Charles took part in 372 public engagements last year, even after stepping aside for almost three months because of cancer ...
Johnson & Johnson has pulled ahead of rival AstraZeneca Plc in a race to dominate the blockbuster market for lung cancer ...
The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...
SAN ANTONIO, March 26, 2025--bioAffinity Technologies' CyPath Lung test uncovered a hidden second primary lung cancer in a patient who had been treated for lung cancer earlier.
Research assessing the nutritional status and impact of interventions for patients with lung cancer found that most exhibit ...
BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...
Report commissioned by govt analysed cost-effectiveness of 2 medicines, comparing them to to chemo in patients with newly ...
Ochsner Lafayette General Medical Center performed its first procedure with the Ion robotic-assisted bronchoscopy system; ...
A groundbreaking study has revealed a significant link between the frequency of chest X-ray referrals from GPs and earlier ...
"Lung cancer ranks third in terms of new cases but second in terms of mortality in Vietnam. Of the over 24,000 new cases ...
First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ...
Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...